Abstracts tagged "mouse model and therapeutic targeting"

Abstract Number: 463 • 2016 ACR/ARHP Annual Meeting
Deficiency of Transmembrane Protein VISTA (V-domain Immunoglobulin Suppressor of T-cell Activation) Ameliorates Murine Collagen-II Antibody-Induced Arthritis
Roy Fava^1,2, Sabrina Ceeraz³, Susan Eszterhas⁴, Petra Sergent³, Christopher Burns⁵ and Mathew Vincenti^6,7, ¹Research, Department of Veterans Affairs, White River Junction, VT, ²Department of Medicinee, Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Microbiology/Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁴Research, Department of Veterans Affairs, white River Junction, VT, ⁵Section of Rheumatology, Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁶Department of Veterans Affairs, White River Junction, VT, ⁷Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: The transmembrane protein VISTA, is a member of the B7/CD28 family of immune modulator proteins and can function as a negative immune checkpoint regulator…
Abstract Number: 2565 • 2015 ACR/ARHP Annual Meeting
ACPA Specific IVIG Attenuate Collagen Induced Arthritis in Mice
Shaye Kivity¹, Nina Svetliscky¹, Qusim Odeh¹, Smadar Gertel¹, Howard Amital¹, Omer Gendelman¹, Iris Barshack², Alexander Volkov², Eran Bar-Meir³, Miri Blank¹ and Yehuda Shoenfeld⁴, ¹Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ²Sheba Medical Center, Institute of Pathology, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ³Plastic surgeon Poria Medical Center affiliated to Faculty of medicine in the Galilee Bar-Ilan university, Poria, Israel, ⁴Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel
Background/Purpose: Administration of intravenous-immunoglobulin (IVIg) is a recognized safe and efficient immunomodulatore therapy for many autoimmune diseases. Anti-idiotypic antibody binding to pathogenic autoantibodies was proposed…
Abstract Number: 39 • 2013 ACR/ARHP Annual Meeting
Chaperone-Mediated Autophagy As a Target Of Therapeutic P140 Peptide Used In Lupus
Sylviane Muller, Institut de Biologie Moléculaire et Cellulaire, CNRS, Strasbourg, France
Background/Purpose: In the pipeline of molecules with a potential for treating lupus patients, the P140 peptide/Lupuzor holds a lot of promise. P140 is a 21-mer…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].